Roy Vitkon

6PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursLiquid biopsiesPredictive and prognostic markersMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

|May 13, 2026
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

|Mar 09, 2026
Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.

Yotam Bronstein, Roy Vitkon, Lucille Hayman

|Feb 11, 2023
Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma.

Or Atar, Ron Ram, Irit Avivi

|Aug 13, 2021
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.

C Perry, E Luttwak, R Balaban

|Aug 11, 2021
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

Roy Vitkon, Dan Netanely, Shai Levi

Pageof 1

Frequent Collaborators

1 joint publications

R Balaban

1 joint publications

A Aharon

1 joint publications

M Levin

1 joint publications

Y Herishanu